Sublingual immunotherapy (SLIT) has been used for more than three decades as a therapeutic strategy for the treatment of allergic diseases. Studies have demonstrated its efficacy and safety, and numerous clinical trials have evaluated these parameters. In the present study, through patient perception, we investigated the patient satisfaction with the use of house dust mite SLIT treatment. “Satisfaction Scale for Patients Receiving Allergen Immunotherapy” (ESPIA) questionnaire, a standardized and validated instrument for clinical studies evaluating allergen immunotherapy, was applied to allergic patients (N = 136). Children and adults of both sexes who received SLIT for Dermatophagoides pteronyssinus and/or Blomia tropicalis, according to the results of an immediate reading puncture test, were included. Data analysis showed that the perception of treatment effectiveness was 92%, performance improvement in the daily activities was 91%, a satisfactory cost-benefit balance was 84%, and the perception of general satisfaction was 97%. The results showed a high perception of satisfaction in allergic patients undergoing house dust mite SLIT.

舌下免疫疗法 (SLIT) 已被用作治疗过敏性疾病的治疗策略超过三十年。研究已经证明了其有效性和安全性，并且许多临床试验已经评估了这些参数。在本研究中，通过患者的感知，我们调查了患者对屋尘螨 SLIT 治疗的满意度。“接受过敏原免疫治疗的患者满意度量表”（ESPIA）问卷是一种用于评估过敏原免疫治疗的临床研究标准化和经过验证的工具，适用于过敏患者（N = 136）。因屋尘螨和/或热带布洛米亚而接受 SLIT 的男女儿童和成人，根据立即阅读穿刺测试的结果，被包括在内。数据分析显示，治疗效果的感知为92%，日常活动中的绩效改善为91%，成本效益平衡的满意率为84%，总体满意度的感知为97%。结果表明，接受屋尘螨 SLIT 的过敏患者的满意度很高。